Innoviva Aims For A First-In-Class Antibiotic
Zoliflodacin could become the first new antibiotic for treating gonorrhea in decades, but can it change guidelines?
You may also be interested in...
Obesity drug pemvidutide looks better at nearly a year than it did at six months, but still lags rivals Wegovy and Zepbound.
The investment wings of big biopharma are taking part in a larger proportion of VC deals than ever before.
Heart disease seems impervious to cell therapy approaches. Is biomarker stratification the answer?